CClinicalTrials.gg
CompletedNCT01951534BRDAUpdated Jan 24, 2017

Decisional Aid Intervention for Women Considering Breast Reconstruction

An interventional study of Breast Reconstruction Decisional Aid (BRDA) and Usual Care in Breast Cancer, sponsored by Rutgers, The State University of New Jersey. Completed at 9 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-24.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is an intervention development and pilot study whose purpose is to determine the feasibility and acceptability of the breast reconstruction decisional aid (BRDA) and provide preliminary data on its impact on decisional outcomes.

The primary aim of this study is: "Is the intervention trial feasible?" The purpose is to develop a feasible web-based decisional aid (DA) for a larger scale trial. Thus it is important that this trial provide evidence of feasibility. The investigators will define feasibility as the rate of study acceptance and participation.

The secondary aim of this study is: " Is the BRDA acceptable and used?" The team will evaluate BRDA acceptability, use, difficulty with internet use, and what factors predict uptake and use. The investigators anticipate that, due to interest in the topic, the majority of women will access the website.

An additional secondary aim of this study is: "What is the impact of BRDA on BR knowledge, attitudes about BR, decisional conflict, preparedness and completeness of preparation, anxiety, and discussion with oncologist?" The purpose is to calculate effect sizes for a larger randomized trial.

02

Conditions studied

  • Breast Cancer

Keywords

  • breast reconstruction
03

In context

Lead sponsor

Rutgers, The State University of New Jersey is the lead sponsor of 496 studies on the registry; 130 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 30 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Patient is scheduled for a surgical consult with a breast surgeon
  • Primary diagnosis of Stage 0 (Ductal Carcinoma in situ), 1, 2, or 3a breast cancer
  • Patient speaks and reads English
  • Patient is considering mastectomy

Exclusion criteria

Exclusion Criteria:

  • Patient who selects lumpectomy and not mastectomy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Breast Reconstruction Decisional Aid (BRDA)

    In the BRDA arm, participants will be provided with a website address for using the Breast Reconstruction Decisional Aid, a secure password, and instructions for using the website for the decisional aid.

    Behavioral: Breast Reconstruction Decisional Aid (BRDA)

  • Other
    Usual Care (UC)

    In the UC Condition, the participant will not be given the web-based decisional aid but will be given the Cancer Support Community pamphlet. This 56-page pamphlet contains information about the types of Breast Reconstruction, lists reasons why women choose reconstruction, key factors to considering when deciding, how to plan for surgery, possible risks, and a glossary of terms. The pamphlet is primarily informational. It is not customized, not interactive.

    Behavioral: Usual Care

Interventions

  • BehavioralBreast Reconstruction Decisional Aid (BRDA)
  • BehavioralUsual Care
06

What researchers measure

Primary outcomes

  1. Feasibility of a decisional aid to assist women with making the decision to undergo breast reconstruction

    We will define feasibility as the rate of study acceptance and participation. First, we will examine acceptance as determined by consents and completed baselines. Second, we will examine time for completing surveys. We will judge this trial feasible if: 1) the acceptance rate among eligible patients is equal to or greater than 70%. We will judge completion rates at follow-up to be feasible for a larger scale trial if our completion rate is 75%. 2) If the survey length averages are \> 35 minutes, we will deem this unacceptable and shorten the survey.

    Time frame: 3 years

Secondary outcomes

  1. Acceptability of BRDA

    We will define acceptability using both quantitative and qualitative methods. Basic descriptive information will be automatically gathered from the DA tracking system regarding whether participants logged in, how many times, and for how long. Time spent in each module will be tracked and summarized. Participants will rate the DA and provide interview feedback regarding its ease of use. Interview feedback regarding home versus public access will be gathered. A second indicator of acceptability will be ratings on the DA evaluation and interview. The range of items on the scale is 1-7. An item mean of 4 is mid-range. We judge our intervention as acceptable if 75% of BRDA participants used the DA and if the average score on the evaluation was \> 5.6, which is 80% of the highest score.

    Time frame: 3 years

  2. Impact of breast reconstruction decisional aid on knowledge and attitudes

    This is an exploratory objective to calculate effect sizes for a larger randomized trial. Using survey data that we will collect as part of this research, we will look at the impact of BRDA on knowledge and attitudes.

    Time frame: 3 years

07

Study locations

9 sites
  • Ocean Medical Center
    Brick, New Jersey 08742, United States
  • Cooper Hospital/University Medical Center
    Camden, New Jersey 08103, United States
  • Bayshore Community Hospital
    Holmdel, New Jersey 07733, United States
  • Southern Ocean Medical Center
    Manahawkin, New Jersey 08050, United States
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07754, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Riverview Medical Center
    Red Bank, New Jersey 07701, United States
  • Somerset Medical Center
    Somerville, New Jersey, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01951534
Lead sponsor
Rutgers, The State University of New Jersey
Collaborators
National Cancer Institute (NCI), Rutgers Cancer Institute of New Jersey
Responsible party
Sponsor
First posted
Sep 26, 2013
Start date
Jan 2011
Primary completion
Jun 30, 2015
Completion
Jun 7, 2016
Last update
Jan 24, 2017

Study contacts

Sharon Manne, PhD
principal investigator · Rutgers Cancer Institute of New Jersey

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion